Search

Your search keyword '"M. Shigekiyo"' showing total 8 results
Start Over Author "M. Shigekiyo"
8 results on '"M. Shigekiyo"'

1. Saturday, 25 August 2012

Author

A. Welz, B. V. Antwerp, A Di Cori, A. Hager, P. Hatzigiannis, R. De Lucia, C. Yu, A. Apor, M. Niemann, R. Sampognaro, M. Fiuza, M. G. Charlot, N. Cortez Dias, A. Nagae, A. Maciag, T. Sato, M. Valgimigli, D. Levorato, S. Herrmann, T. Kimura, M. Luedde, V. Tzamou, M. Iwabuchi, C. Rickers, J. Sobierajski, J. Vecera, C. Vlachopoulos, K. Goscinska-Bis, S. Goldsmith, H. Ueno, J. Sosna, G. Malerba, W. Li, H. W. Lee, K. Bogaard, K. Yamada, A. Mateo-Martinez, J. Navarova, M. Zeman, K. Dimopoulos, M. P. Lopez Lereu, E. Pelissero, B. Gersak, J. M. Tolosana, S Manzano Fernandez, P. Mertens, J. J. M. Takkenberg, J. W. Kim, R.T. van Domburg, G. P. Diller, H. M. Yang, F. Gustafsson, P. G. Golzio, G. S. Hwang, J. Brugada, S. Stoerk, J. Hess, Y. Cavusoglu, L. Segreti, M. E. Trucco, C. Jacoby, I. Bafakis, T. Isshiuki, L. Pulpon, S. Pires, L. Paperini, A. Cremonesi, H. Baumgartner, C. Tsioufis, M. Valdes-Chavarri, S. Schaefer, M. Totzeck, A. Bochenek, F. Saia, P. Carrilho-Ferreira, M. Khatib, E. M. W. J. Utens, G. Zucchelli, R. Jenni, E. Gencer, N. Carter, A. Kovacs, C. Linde, V. Monivas, A. Marzocchi, L. Baerfacker, L. Mont, R. Weber, F. J. Enguita, T. L. Bergemann, M. Chudzik, A. Chernyavskiy, D. Dragulescu, S. Orwat, B. J. Choi, P. Opic, C. Torp-Pedersen, F. Gaita, V. A. W. M. Umans, A. Lopez-Cuenca, S. B. Christensen, E. C. Bertolino, D. Tousoulis, F. Weidemann, H. H. Kramer, J. Greenslade, J Cosin Sales, M. Gonzalez Estecha, W. Grosso Marra, T. Katsimichas, J. Hoerer, S. Mingo, M. Hochadel, M. A. Castel, M. S. Lattarulo, E. Y. Yun, K. Fattouch, H. S. Lim, A. Uebing, T. Ulus, J. Radosinska, A. Castro Beiras, J. Peteiro, M. Koren, C. Prados, A. Nunes, C. Rammos, C. Thomopoulos, T. Kameyama, F. Borgia, I. Voges, J. L. Looi, L. Cullen, C. Campo, J. Bis, S. Shiva, H. Kato, N. Frey, E. Andrikou, G. H. Gislason, J. Ruvira, A. Kasiakogias, S. Robalo Martins, A. M. Zimmer, M. H. Yacoub, M. Nobuyoshi, U. Zeymer, K. Hanazawa, F. J. Broullon, B. Petracci, K. Hu, A. Petrescu, A. M. Maceira Gonzalez, K. Harada, L. Swan, C. Felix, H. Inoue, T. Haraguchi, N. Cortez-Dias, S. Bisetti, P. Mitkowski, C. Daubert, H. J. Heuvelman, M. R. Gold, G. P. Kimman, O. Gaemperli, H. C. Lee, Y. Takasawa, V. Monivas Palomero, A. C. Andrade, S. Maddock, W. Budts, M. Penicka, F. J. Ten Cate, M. Czajkowski, C. D. Nguyen, K. Kaitani, K. Kintis, S. Castrovinci, D. Liu, T. Benova, K. W. Seo, B. A. Herzog, A. Ionac, C. Jorge, M. Iacoviello, S. Kuramitsu, Y. Nakagawa, K. U. Mert, A. Manari, S. Brili, R. Alonso-Gonzalez, A. J. Six, J. S. Mcghie, A. Goedecke, M. Kelm, F. C. Tanner, F. Marin, C. I. Santos De Sousa, L. Kober, M. Frigerio, D. Adam, B. E. Backus, U. Hendgen-Cotta, A. Belo, D. Couto Mallon, M. Dewor, M. Madsen, J. H. Shin, M. H. Yoon, L. Maiz, P. Lancellotti, A. Nunes Diogo, G. Ertl, R. Pietura, A. Mornos, M. Than, C. Andersson, C. Izumi, E. Liodakis, N. van Boven, Y. Y. Lam, T. Hansen, W. Roell, T. J. Hong, P. Luedicke, M. Sanchez-Martinez, L. Ruiz Bautista, E. N. Oechslin, T. Klaas, M. T. Martinez, W. A. Helbing, J. L. Januzzi, S. Parra-Pallares, A. Romanov, B. Sax, D. Prokhorova, P. Guastaroba, D. Silva, A. Karaskov, P. Kolkhof, B. Bouzas Zubeldia, T. Rassaf, M. Costa, C. Viczenczova, V. Antoncecchi, A. Kempny, J. Bartunek, I. Kardys, J. H. Ahn, C. Hart, A. Berruezo, C. Vittori, W. Vletter, M. Shigekiyo, S. Knob, V. Marangelli, R. Borras, A E Van Den Bosch, S. Y. Choi, E. Arbelo, G. Lazaros, T. Arita, G. Suchan, T. Nakadate, D. Van Der Linde, E. Pokushalov, K. Ando, J. Neutel, P. Biaggi, C. Mornos, R. Corti, M. Landolina, B. Merkely, B. Malecka, H. J. Hippe, S. J. Tahk, J. Aguilar, G. Piovaccari, M. Lutz, D. Rizopoulos, N. Alvarez Garcia, M. Cipriani, T. Kumamoto, S. Kubota, M. Sitges, B. K. Fleischmann, G. Caccamo, D. Tsiachris, M. A. Russ, F. Mutlu, A. Menozzi, J. C. Choi, J. V. Monmeneu, J. C. Yanez Wonenburger, N. Tribulova, C. Forleo, M. Vinci, J. W. Roos-Hesselink, O. Bodea, T. Domei, P. W. Lee, A. Puzzovivo, M. Heikenwaelder, F. Ferraris, C. Stefanadis, M. Kempa, M. Vanderheyden, A. Birdane, J. A. A. E. Cuypers, I. Andrikou, G. Casella, P. Stock, S. Favale, B. Bijnens, A. Kretschmer, J. Bernhagen, M. A. Cavero Gibanel, S. Datta, M. E. Menting, S. Viani, T. Heuft, M. Cikes, A. J. J. C. Bogers, J. Estornell, M. Pham, A. Nadir, F. J. Pinto, M. Hyodo, D. Flessas, C. Chrysohoou, O. Dewald, B. Ren, K. Wustmann, J. C. Burnett, T. Noto, G. Ruvolo, M. Witsenburg, E. Soldati, G. D. Duerr, L. Alonso Pulpon, J. H. Oh, A. Zabek, B. Albrecht-Kuepper, V. Antonakis, M. B. Nielsen, T. Huttl, B. Bacova, A. Piorkowski, I. Z. Cabrita, A. Fanelli, M. A. Weber, J. Segovia, A. I. Romero-Aniorte, J. H. Choi, V. Dosenko, C. Wackerl, J. H. Ruiter, H. Yokoi, S. Ghio, V. Knezl, F. Monitillo, M. Morello, M. Jerosch-Herold, M. L. Geleijnse, A. Bouzas Mosquera, R. Fabregas Casal, H. Mudra, J. Gruenenfelder, U. Floegel, L. Petrescu, M. A. Gatzoulis, S. Shizuta, J. Brachmann, M. G. Bongiorni, M. Pringsheim, J. Mueller, A. Nagy, R. Giron, W. T. Abraham, Y. Takabatake, F. Toyota, D. Martinez Ruiz, M. Lunati, S. Vargiu, L E De Groot De Laat, V. Shabanov, L. Lioni, R. Kast, D. Bettex, K. S. Cha, J. L. Diago, D. Cozma, H. Lieu, M. Giakoumis, E. Orenes-Pinero, G. Murana, A. Kutarski, A.P.J. van Dijk, G. Speziale, A. Boem, L. M. Belotti, B. Igual, A. M. S. Olsen, and H. Lue

Subjects
business.industry, Medicine, Ancient history, Cardiology and Cardiovascular Medicine, business
Published
2012
Full Text
View/download PDF

4. Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes: A randomized, controlled trial.

Author

Harada K, Yamamoto T, Okumura T, Shigekiyo M, Terada N, Okada A, Kawata A, Iima T, Harada T, Fujisawa K, Kageyama N, Saito A, Yamamoto H, and Fujinaga H

Subjects
Aged, Aged, 80 and over, Diastole drug effects, Dyspnea drug therapy, Echocardiography drug effects, Echocardiography instrumentation, Emergency Service, Hospital, Female, Heart Failure physiopathology, Hemodynamics drug effects, Humans, Infusions, Intravenous, Japan epidemiology, Male, Middle Aged, Nicorandil pharmacology, Nitroglycerin therapeutic use, Outcome Assessment, Health Care, Prospective Studies, Treatment Outcome, Vasodilator Agents administration & dosage, Vasodilator Agents pharmacology, Ventricular Function, Left drug effects, Administration, Intravenous methods, Heart Failure drug therapy, Nicorandil administration & dosage
Abstract

Background: Vasodilators, such as nitroglycerin, have long been first-line treatments for acute heart failure syndromes (AHFS). Nicorandil is a vasodilator with dual potassium channel opening and nitrate properties. However, there are no randomized controlled studies of intravenous nicorandil safety and efficacy in the urgent phase AHFS. We examined the symptomatic, hemodynamic, and echocardiographic effects and safety, and 60-day clinical outcomes of intravenous nicorandil, in addition to standard therapy, in patients with AHFS in the urgent phase., Methods: In this prospective, randomized controlled trial, 106 AHFS patients were randomized within one hour of arrival to receive either standard therapy (control group, n=56) or standard therapy plus simultaneous intravenous nicorandil (0.2 mg/kg bolus followed by 0.2 mg/kg/h for 24 h; nicorandil group, n=50). Outcomes were assessed at 60 days., Results: Patients in the nicorandil group exhibited greater improvement of dyspnea as measured by change in a five-point Likert scale compared to those in the control group (after 1 h infusion: p=0.006, 6 h; p<0.001). The nicorandil group also showed significantly improved E/e', an estimate of left ventricular filling pressure, at 1 and 24 h ( p=0.001 and p=0.004, respectively). In addition, intravenous nicorandil therapy was safe and did not cause side effects such as excessive hypotension or reflex tachycardia. However, it did not reduce all-cause mortality and readmission rates at 60 days., Conclusions: Addition of intravenous nicorandil to standard therapy for urgent phase AHFS improved dyspnea and left ventricular diastolic function but not 60-day outcome.

Published
2017
Full Text
View/download PDF

5. Promoter polymorphism in the CD14 gene and concentration of soluble CD14 in patients with in-stent restenosis after elective coronary stenting.

Author

Shimada K, Miyauchi K, Mokuno H, Watanabe Y, Iwama Y, Shigekiyo M, Matsumoto M, Okazaki S, Tanimoto K, Kurata T, Sato H, and Daida H

Subjects
Angina Pectoris therapy, Coronary Restenosis blood, Female, Genetic Markers, Humans, Japan, Lipopolysaccharide Receptors genetics, Male, Middle Aged, Promoter Regions, Genetic, Coronary Restenosis diagnosis, Lipopolysaccharide Receptors blood, Polymorphism, Genetic, Stents
Abstract

Background: Activated monocytes/macrophages, neutrophils, endothelial cells and smooth muscle cells participate in the restenosis processes. Monocytes/macrophages and neutrophils are activated by lipopolysaccharide (LPS) via CD14. Endothelial cells and smooth muscle cells are also stimulated by soluble CD14 (sCD14)-LPS complexes., Methods: We tested the hypothesis that C(-260)-->T polymorphism of the CD14 gene and sCD14 might be predictors for in-stent restenosis. We analyzed 129 consecutive patients who underwent elective coronary stenting. The restenosis was defined as > or =50% diameter stenosis at follow-up angiography., Results: The prevalence of the T/T genotype and the concentration of sCD14 were significantly higher in the restenosis group than in the no-restenosis group. This CD14 polymorphism also affected the levels of sCD14, therefore, we divided the patients into four groups. The loss index was 24.8% in C/C or C/T and < or =50th percentile of sCD14, 35.9% in T/T and < or =50th percentile of sCD14, 44.2% in C/C or C/T and >50th percentile of sCD14, and 49.1% in T/T and >50th percentile of sCD14 (P=0.02). The restenosis rate was 10.0%, 26.7%, 26.2% and 50.0% in each group, respectively (P=0.003). In the multivariate analysis, T/T and >50th percentile of sCD14 was the independent predictor for in-stent restenosis., Conclusions: This study showed that the T/T genotype with a high level of sCD14 is an independent predictor of in-stent restenosis. The activation of monocytes/macrophages, endothelial cells and smooth muscle cells mediated by CD14 and/or sCD14 may play an important role in the restenosis processes.

Published
2004
Full Text
View/download PDF

6. Predictive value of the adipocyte-derived plasma protein adiponectin for restenosis after elective coronary stenting.

Author

Shimada K, Miyauchi K, Mokuno H, Miyazaki T, Seki E, Watanabe Y, Iwama Y, Shigekiyo M, Matsumoto M, Okazaki S, Tanimoto K, Kawamura M, Suzuki H, Kurata T, Sato H, and Daida H

Subjects
Adiponectin, Coronary Angiography, Coronary Restenosis diagnostic imaging, Coronary Vessels, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Risk Factors, Coronary Disease surgery, Coronary Restenosis diagnosis, Elective Surgical Procedures, Intercellular Signaling Peptides and Proteins, Proteins analysis, Stents
Abstract

The purpose of this study was to test the hypothesis that plasma levels of adiponectin can predict angiographic in-stent restenosis after coronary stenting. We prospectively examined adiponectin levels in 127 consecutive patients undergoing elective coronary stenting. Restenosis was defined as more than 50% stenosis at follow-up study by quantitative coronary angiography. There were no significant differences in the clinical characteristics or angiographical findings between the groups with restenosis and no restenosis. The levels of adiponectin did not differ between the restenosis group and the no restenosis group (5.7 +/- 2.8 vs 5.9 +/- 3.6 microg/mL, p = 0.72). The plasma levels of adiponectin were not related with the late loss index after coronary stenting (r = 0.01, p = 0.89). The levels of adiponectin were significantly lower in men than in women (5.5 +/- 3.2 vs 8.8 +/- 3.7 microg/ mL, p < 0.001), and negatively correlated with body mass index (r = -0.21, p = 0.01). We analyzed adiponectin levels in male, female, obese, non-obese, diabetes, and non-diabetes patients, however, there were no significant differences between the restenosis group and no restenosis group. This study has demonstrated that the measurement of adiponectin could not predict angiographic restenosis after elective coronary stenting, whereas the plasma levels of adiponectin were associated with some coronary risk factors in patients with coronary artery disease.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results